date of publication:01.10.2021 | 17:47 GMT | the health
The American company “Merck” has developed a drug in the form of tablets that may represent a breakthrough in the treatment of the Corona virus, and according to experts, the drug is able to halve the chances of death or hospitalization.
If approved, melnopiravir tablets, which are designed to implant errors in the virus’ genetic code, will be the first oral antiviral drug to treat Covid-19.
Merck and partner Ridgeback Biotherapeutics plan to obtain emergency use authorization in the United States as soon as possible, before submitting applications to drug regulators around the world.
“This treatment will fundamentally change the methods of controlling Covid-19,” said Robert Davis, CEO of Merck.
“The rules of the game will change because oral antivirals can affect the risk of hospitalization to this extent,” said Amish Adalia, a researcher at the Johns Hopkins Center for Health Security.
Compared to current treatments that are “comfortable and logistically difficult”, Adalja says, “taking a simple oral tablet would be the opposite.”
Because of the positive results, “Merck” shares rose by more than 9 percent at the start of trading in New York, while “Pfizer” shares fell by 3 percent, and “Moderna” fell by 10 percent, two companies that manufacture Covid-19 vaccines.